Novel approaches—such as bispecific antibodies designed to simultaneously target CTLA-4 and PD-1, as well as therapies directed against CCR8, GITR, and TIGIT—seek to selectively deplete or reprogram tumor-infiltrating Tregs. This evidence concerns the gene CCR8 and neoplasm.